{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-390652","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-09-14T20:30:17+00:00","discovered_at":"2026-09-14T20:32:13.120482+00:00","generated_at":"2026-09-14T20:33:41.525010+00:00","sec_items":["2.01","9.01","5.02"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Quince Therapeutics sells A-T assets to Ayma for $450K; President Ryan departs","bullets":["Completed sale of Quince SpA, AIDE IP, and eDSP machines to Ayma Therapeutics for $450,000 cash on Sept 8, 2026.","Sale includes ~55 AIDE/eDSP machines: ~20 at Italian facilities, ~35 at clinical trial sites.","President Charles Ryan separated Sept 8, 2026; severance of $1,014,489.04 under Separation Agreement.","Pro forma financials assume sale effective Jan 1, 2025 for operations; balance sheet as of June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-390652","json":"https://secwatch.observer/filing/0001193125-26-390652.json","markdown":"https://secwatch.observer/filing/0001193125-26-390652.md","text":"https://secwatch.observer/filing/0001193125-26-390652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526390652/0001193125-26-390652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526390652/qncx-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T20:33:41.525010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}